This federal Project Grant award of $3,256,360, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a study titled "The Doxy-PEP Impact Study: A Multi-City US Longitudinal Cohort to Evaluate Doxy-PEP Field Effectiveness, Investigate Associated Antimicrobial Resistance, and Establish Doxy-PEP to Need Ratios." The key objectives of this study are to: 1) Evaluate the...
This $195,480 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and pilot implementation of a low-cost, point-of-care diagnostic assay to detect Neisseria gonorrhoeae infection and molecular markers of antimicrobial resistance in resource-limited settings. The award recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,516 to Vanderbilt University Medical Center to conduct pharmacokinetic assessments of short-course rifapentine for tuberculosis (TB) preventive therapy in people living with HIV taking dolutegravir, children under 12 years, and pregnant women. The project aims to confirm that model-informed dosing of TB and HIV...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the efficacy of therapeutic drug monitoring (TDM) in preventing premature discontinuation of the antibiotic linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The $766,877 award will fund a pragmatic, randomized clinical trial at a research site in South Africa. The study...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,233,520 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, titled "CHIPP-PREP: CABOTEGRAVIR-HORMONE INTERROGATION OF PHARMACOKINETICS/PHARMACODYNAMICS FOR HIV PREVENTION IN CISGENDER AND TRANSGENDER PERSONS," aims to improve HIV prevention for transgender women and gender diverse persons accessing estrogen-based gender...
The National Institute of Nursing Research (NINR) awarded a $114,866 Project Grant (CFDA 93.361 - Nursing Research) to The Ohio State University to conduct a mixed methods study on improving awareness, uptake, and persistence of biomedical HIV and sexually transmitted infection (STI) prevention strategies, such as pre-exposure prophylaxis (PrEP) and doxycycline post-exposure prophylaxis (DoxYPEP), in primary care settings. The study aims to (1) describe approaches from the perspectives of sexual...
This $267,000 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund a study to assess the clinical and implementation outcomes of a point-of-care sexually transmitted infection (STI) testing strategy to improve HIV prevention service delivery in adolescents. The research will be conducted by the Icahn School of Medicine at Mount Sinai. The study aims to evaluate how a new point-of-care testing modality for gonorrhea and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $702,000 to support a 3-year project aimed at optimizing the implementation of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention. The key objectives are to: 1) Identify barriers and facilitators to LAI-PrEP implementation, 2) Determine optimal implementation strategies in partnership with...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to comprehensively investigate the extent and impact of transmitted and acquired HIV drug resistance in Kenya as the country transitions to widespread use of dolutegravir-based antiretroviral therapy. The $645,900 award, with a project period from September 2024 to July 2029, will fund a prospective study to...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a novel suite of local-level syphilis epidemiologic and economic models (LSEEM) across 40 U.S. cities with the highest syphilis diagnosis rates. The $1,550,917 award, spanning from July 2024 to May 2029, aims to assess the potential impact of scaling up existing syphilis control...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will provide $1,563,642 to support a randomized, directly observed therapy (DOT) study to interpret clinical trials of doxycycline post-exposure prophylaxis (doxy-PEP) for preventing bacterial sexually transmitted infections (STIs).
The study aims to: 1) Develop in-depth pharmacokinetic measurement techniques for doxycycline through a randomized crossover DOT study with 36 participants, 2) Examine adherence patterns in previous doxy-PEP trials to establish thresholds of doxycycline levels in hair, urine, and plasma that can be used to interpret adherence in future studies, and 3) Analyze the relationship between adherence patterns and STI incidence reduction in the DPEP trial. A $135,791 sub-award will support the project director from the Hennepin Healthcare Research Institute, who will provide archived hair samples and behavioral data from a related clinical trial to assist with the pharmacokinetic modeling and adherence analysis.